Support for Your Patients Taking Qelbree (Viloxazine Extended-Release Capsules)

The Qelbree team is committed to supporting Attention-Deficit/Hyperactivity Disorder (ADHD) patients and their families. Many helpful resources are available to support you and your patients taking Qelbree.¹

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

Please see full Important Safety Information to the top left.

Samples & Support Programs

Request Samples

Starting your patients on Qelbree is easy with online sample ordering.¹ Requested samples can be delivered to a doctor’s office.¹ For more information, visit here.

Patient Support

Patients taking Qelbree can also benefit from the Qelbree Patient Savings and Support Program.¹ Supernus is committed to helping patients access the care they need. Qelbree offers a Savings Card to eligible patients. Commercially insured patients may pay as little as $20 per prescription, terms and conditions apply. Health care providers can provide patients with access to this Savings Card by emailing or printing the Savings Card.¹ Find more information here.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

• Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
• Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

Please see full Important Safety Information to the top left.

Additional Services 

CoverMyMeds

CoverMyMeds is a HIPAA-compliant website that helps you streamline and automate your prior authorization process.² 

Supernus Support

Health care providers and patients also have a direct line of contact for all questions and assistance for Qelbree through Supernus Support.¹ Reach Supernus Support at 1-866-398-0833 Monday-Friday, 8:30AM-6:30PM ET (excluding holidays).

Educational Resources

Health care providers can visit QelbreeHCP.com to access additional resources on dosing information, safety information, requesting samples, requesting a representative, and full prescribing information.¹

Providers can also access a helpful diagnosing guide here.  

IMPORTANT SAFETY INFORMATION

• Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes 

Please see full Important Safety Information to the top left. 

Request a Representative

Doctors who are interested in learning more about Qelbree can request to be contacted directly by a Supernus representative!¹ For more information and access to a sales representative, visit here.

Full Prescribing Information

You can read about Qelbree’s indication and usage, its dosage forms and strengths, as well as about the four clinical trials demonstrating the safety and efficacy in ADHD patients 6 years and older.³ See the full prescribing information, including Boxed Warning, for Qelbree here.³

Learn more about Qelbree, an extended-release, nonstimulant medication for ADHD: https://www.QelbreeHCP.com/.

References:

1. QelbreeHCP.com. Updated 2022. Accessed: January 10, 2024. https://www.qelbreehcp.com/
2. Covermymeds. Updated 2022. Accessed: January 10, 2024. https://www.covermymeds.com/main/about/
3. Qelbree Prescribing Information. Rockville, MD: Supernus Pharmaceuticals. Accessed January 10, 2024. https://www.supernus.com/sites/default/files/Qelbree-Prescribing-Info.pdf

QBE.2022-0355 V2